**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:**  CAN/2015-16/XYZ

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | LAMIVUDINE / NEVIRAPINE / ZIDOVUDINE DISPERSIBLE TABLETS 30 mg/50 mg/60 mg | | REF. NO: NDQD201508148 |
| **DATE RECEIVED:** 06.08.2015 | **LABEL CLAIM:** | Each dispersible tablet contains: Lamivudine USP 30 mg, Nevirapine USP 50 mg, Zidovudine USP 60 mg. | |
| **BATCH NO.:** 3022261 | **PRESENTATION:** | Cream coloured, circular shaped, flat faced beveled-edged tablets, single scored and embossed 'M09" on half-side of the scored face, packed in a white plastic multi-dose container carrying 60 tablets in a unit box. | |
| **MGF. DATE:** Jan. 2014 | **MANUFACTURER:** | MYLAN Laboratories Ltd. | |
| **EXP. DATE:** Dec. 2018 | **ADDRESS:** | H-12 & H-13, MIDC, Waluj, Aurangabad-431136, Maharashtra, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | National AIDS and STI Control Programme P.O. BOX 19361 Nairobi | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | B.P. 2012 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean tablet weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC:HPLC:HPLC | Adopted In-House Method | RT of the component peaks in the assay sample preparation correspond to those in the assay standard preparation | Super-imposable peaks at RT 2.9, 3.8 and 5.3 Â± 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC:HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Lamivudine; 99.0% (RSD = 7.5% ; n = 6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Nevirapine; 95.6% (RSD = 4.9% ; n = 6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Zidovudine; 100.4% (RSD = 4.7% ; n = 6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | Lamivudine 101.9% (RSD = 1.8% ; n = 9) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | Nevirapine 99.6% (RSD = 1.1%; n = 9) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | Zidovudine; 101.9% (RSD = 0.3%; n = 6) | **COMPLIES:COMPLIES:COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  | DATE: |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:11-02-2015 |